Invention Grant
- Patent Title: Inhibitors of EZH2
-
Application No.: US15242638Application Date: 2016-08-22
-
Publication No.: US09718838B2Publication Date: 2017-08-01
- Inventor: Deqi Guo , Anh-Quan Hannah Nguyen , Michael Enrico Richett
- Applicant: Eli Lilly and Company
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Tina M. Tucker
- Priority: EP15382433 20150827; EP15382615 20151211
- Main IPC: C07D495/04
- IPC: C07D495/04 ; A61K31/5377 ; A61K31/337 ; A61K31/282 ; A61K31/55 ; A61K33/24 ; A61K31/7068 ; A61K31/444 ; A61K31/4745
Abstract:
The present invention relates to compounds that inhibit activity of the histone lysine methyltransferase, Enhancer of Zeste Homolog 2 (EZH2), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, such as hematologic and solid tumors.
Public/Granted literature
- US20170066780A1 INHIBITORS OF EZH2 Public/Granted day:2017-03-09
Information query
